Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes

Summary Aims: The study investigated the clinical equivalence in reducing haemoglobin A1c (A1C) between glimepiride/metformin sustained release (GM‐SR) 2/500 mg, a fixed‐dose combination, once daily and glimepiride/metformin (GM) 1/250 mg, a fixed‐dose combination, twice daily in patients with type...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of clinical practice (Esher) 2013-03, Vol.67 (3), p.236-243
Hauptverfasser:	Hwang, Y.-C., Kang, M., Ahn, C. W., Park, J. S., Baik, S. H., Chung, D. J., Jang, H. C., Kim, K.-A., Lee, I.-K., Min, K. W., Nam, M., Park, T. S., Son, S. M., Sung, Y.-A., Woo, J.-T., Park, K. S., Lee, M.-K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Blood Glucose - metabolism Delayed-Action Preparations Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Double-Blind Method Drug Administration Schedule Drug therapy Female Glycated Hemoglobin A - metabolism Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Male Medication Adherence Metformin - administration & dosage Metformin - adverse effects Middle Aged Patients Safety Sulfonylurea Compounds - administration & dosage Sulfonylurea Compounds - adverse effects Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary Aims: The study investigated the clinical equivalence in reducing haemoglobin A1c (A1C) between glimepiride/metformin sustained release (GM‐SR) 2/500 mg, a fixed‐dose combination, once daily and glimepiride/metformin (GM) 1/250 mg, a fixed‐dose combination, twice daily in patients with type 2 diabetes (T2D). Methods: A multicentre, randomised, double‐blind, double‐dummy study was conducted in 14 hospitals in Korea. Inclusion criteria were age 30–75 years, T2D diagnosis no longer than 10 years previously, A1C between 7% and 10%, and body mass index
ISSN:	1368-5031 1742-1241
DOI:	10.1111/ijcp.12071